ReviewCurrent microbiology2025
Clostridium chauvoei Antigens: Applications, Available Options and Potential Alternatives in the Future.
Review in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium chauvoei is a gram-positive spore-forming anaerobic bacterium and the cause of blackleg, a highly fatal endogenous disease in ruminants. The bacterium produces both cellular (somatic and flagellar) and soluble antigens (toxins) that contribute to the pathogenesis. Immunity to C. chauvoei is primarily anti-bacterial, and so the traditional vaccines are formalinized whole-culture bacterins. The current research focuses on identifying specific antigens as immuno-protective antigens including cell surface or flagellar proteins or soluble antigens. This paper summarizes the application of C. chauvoei immunogens for detection or vaccine quality control, and reviews the ongoing research into developing more targeted subunit vaccines using recombinant or purified antigens like CctA or flagellin. Despite high genomic similarity in virulence factors among C. chauvoei strains, differences in the fliC gene encoding flagellin exist. Hence, strain differences may affect the protection efficacy against Blackleg disease. The development of effective Blackleg subunit vaccines necessitates careful consideration of the C. chauvoei strain, antigen purification techniques, bacterial growth phase and the preservation of crucial conformational epitopes in recombinant technology.
Indexed as
Identifiers
41081857What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.